Henry Marianne P, Hawkins J Ross, Boyle Jennifer, Bridger Joanna M
Advanced Therapies Division, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.
Laboratory of Nuclear and Genomic Health, Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University London, London, United Kingdom.
Front Genet. 2019 Jan 21;9:623. doi: 10.3389/fgene.2018.00623. eCollection 2018.
Human pluripotent stem cells (hPSCs) are increasingly used for cell-based regenerative therapies worldwide, with embryonic and induced pluripotent stem cells as potential treatments for debilitating and chronic conditions, such as age-related macular degeneration, Parkinson's disease, spinal cord injuries, and type 1 diabetes. However, with the level of genomic anomalies stem cells generate in culture, their safety may be in question. Specifically, hPSCs frequently acquire chromosomal abnormalities, often with gains or losses of whole chromosomes. This review discusses how important it is to efficiently and sensitively detect hPSC aneuploidies, to understand how these aneuploidies arise, consider the consequences for the cell, and indeed the individual to whom aneuploid cells may be administered.
人类多能干细胞(hPSC)在全球范围内越来越多地用于基于细胞的再生疗法,胚胎干细胞和诱导多能干细胞是治疗衰弱性和慢性疾病的潜在疗法,如年龄相关性黄斑变性、帕金森病、脊髓损伤和1型糖尿病。然而,鉴于干细胞在培养过程中产生的基因组异常水平,其安全性可能受到质疑。具体而言,hPSC经常获得染色体异常,通常是整条染色体的增加或减少。本文综述了高效、灵敏地检测hPSC非整倍体的重要性,以了解这些非整倍体是如何产生的,考虑其对细胞以及可能接受非整倍体细胞治疗的个体的影响。